Spyglass Pharma, Inc.’s Quiet Period Will Expire on March 18th (NASDAQ:SGP)

HC Wainwright began coverage of Spyglass Pharma (NASDAQ:SGP) on Tuesday, issuing a buy rating and $37.00 price objective. Jefferies also started coverage on March 3, giving a buy rating and $62.00 target. Wall Street Zen upgraded to hold on Feb 17. Spyglass’s quiet period ends March 18, following a Feb 6 IPO of 9.375M shares at $16.00, raising $150M.